[Clinical evaluation of a combination treatment with cefminox and fosfomycin for infections complicated in patients with hematological disorders].
We evaluated clinical effects and toxicities of a combination treatment with cefminox (CMNX) and fosfomycin (FOM) for infections complicated with hematological disorders in 56 patients. Among those, 52 patients including 22 with malignant lymphoma, 19 with acute leukemia, and 11 with other hematological disorders were evaluable. Excellent and good responses were obtained in 33 (63.5%) of the 52 patients. This treatment was also effective in 5 of 9 cases in which granulocyte counts were less than 500/mm3 through the course of administration. Side effects were observed in only one patient. Mild nausea occurred but was not serious. These results indicate that the combination of CMNX and FOM is an effective and safe regimen for the treatment of infections complicated in patients with hematological disorders.
Seriu
T
T
Third Department of Internal Medicine, Kyoto Prefectural University of Medicine.
Tsuda
S
S
Nakai
H
H
Murakami
T
T
Takashima
T
T
Takahashi
Y
Y
Tanaka
S
S
Nakagawa
H
H
Nishigaki
H
H
Yokota
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D002513:Cephamycins / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D005260:Female; D005578:Fosfomycin / Q000008:administration & dosage*; D006402:Hematologic Diseases / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D006801:Humans; D016867:Immunocompromised Host; D007262:Infusions, Intravenous; D007938:Leukemia / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008297:Male; D008875:Middle Aged
D002513:Cephamycins; D005578:Fosfomycin; C046079:cefminox